Association of < em > CYP3A5 < /em > < sup > * < /sup > < em > 3, CYP3A4 < /em > < sup > * < /sup > < em > 18 & amp; CYP2B6 < /em > < sup > * < /sup > < em > 6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients

CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22
Source: The Indian Journal of Medical Research - Category: Biomedical Science Authors: Source Type: research